Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 3OCU410Positive

AI Analysis

Summary

Ocugen announced the first patient dosed in a Phase 3 registrational trial of OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in Phase 3 registrational trial

Importance:6/10

Sentiment:

0.60

gene therapyPhase 3OCU410geographic atrophydry AMDmodifier gene therapy

Related Companies

$OCGN

Read the original article

Published by yahoo_finance on September 1, 2026 11:02 AM

Read Original